vs
PLUMAS BANCORP（PLBC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是PLUMAS BANCORP的1.1倍（$30.3M vs $28.6M），REGENXBIO Inc.同比增速更快（43.0% vs 35.1%），PLUMAS BANCORP自由现金流更多（$20.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 20.8%）
Plumas Bancorp是一家美国银行控股公司，通过旗下子公司Plumas Bank开展业务，为加利福尼亚州北部及内华达州的个人客户、中小企业和本地社区机构提供存款、各类贷款、财富管理等综合零售及商业银行服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PLBC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.1倍
$28.6M
营收增速更快
RGNX
高出7.9%
35.1%
自由现金流更多
PLBC
多$73.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $28.6M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 48.9% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 35.1% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $1.56 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLBCRGNX
| Q4 25 | $28.6M | $30.3M | ||
| Q3 25 | $27.4M | $29.7M | ||
| Q2 25 | $20.5M | $21.4M | ||
| Q1 25 | $21.8M | $89.0M | ||
| Q4 24 | $21.2M | $21.2M | ||
| Q3 24 | $21.1M | $24.2M | ||
| Q2 24 | $20.6M | $22.3M | ||
| Q1 24 | $19.6M | $15.6M |
净利润PLBCRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $5.1M | $-61.9M | ||
| Q2 25 | $6.3M | $-70.9M | ||
| Q1 25 | $7.2M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $7.8M | $-59.6M | ||
| Q2 24 | $6.8M | $-53.0M | ||
| Q1 24 | $6.3M | $-63.3M |
毛利率PLBCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率PLBCRGNX
| Q4 25 | 48.9% | -190.0% | ||
| Q3 25 | 25.2% | -176.3% | ||
| Q2 25 | 42.2% | -296.3% | ||
| Q1 25 | 46.1% | 13.6% | ||
| Q4 24 | 50.3% | -242.1% | ||
| Q3 24 | 50.6% | -256.6% | ||
| Q2 24 | 45.1% | -251.3% | ||
| Q1 24 | 42.8% | -408.8% |
净利率PLBCRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 18.8% | -208.3% | ||
| Q2 25 | 30.8% | -331.8% | ||
| Q1 25 | 33.0% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 37.1% | -246.3% | ||
| Q2 24 | 32.9% | -237.7% | ||
| Q1 24 | 31.9% | -405.4% |
每股收益（稀释后）PLBCRGNX
| Q4 25 | $1.56 | $-1.30 | ||
| Q3 25 | $0.73 | $-1.20 | ||
| Q2 25 | $1.05 | $-1.38 | ||
| Q1 25 | $1.20 | $0.12 | ||
| Q4 24 | $1.30 | $-0.99 | ||
| Q3 24 | $1.31 | $-1.17 | ||
| Q2 24 | $1.14 | $-1.05 | ||
| Q1 24 | $1.05 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $261.1M | $102.7M |
| 总资产 | $2.2B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLBCRGNX
| Q4 25 | $80.6M | $230.1M | ||
| Q3 25 | $87.3M | $274.2M | ||
| Q2 25 | $79.3M | $323.3M | ||
| Q1 25 | $87.3M | $267.9M | ||
| Q4 24 | $82.0M | $234.7M | ||
| Q3 24 | $118.0M | $255.5M | ||
| Q2 24 | $109.9M | $290.4M | ||
| Q1 24 | $128.2M | $338.7M |
股东权益PLBCRGNX
| Q4 25 | $261.1M | $102.7M | ||
| Q3 25 | $245.9M | $161.5M | ||
| Q2 25 | $193.1M | $213.7M | ||
| Q1 25 | $187.6M | $274.2M | ||
| Q4 24 | $177.9M | $259.7M | ||
| Q3 24 | $181.9M | $301.4M | ||
| Q2 24 | $165.2M | $348.3M | ||
| Q1 24 | $161.5M | $390.7M |
总资产PLBCRGNX
| Q4 25 | $2.2B | $453.0M | ||
| Q3 25 | $2.2B | $525.2M | ||
| Q2 25 | $1.6B | $581.0M | ||
| Q1 25 | $1.6B | $490.9M | ||
| Q4 24 | $1.6B | $466.0M | ||
| Q3 24 | $1.7B | $519.1M | ||
| Q2 24 | $1.6B | $569.4M | ||
| Q1 24 | $1.6B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $20.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 70.9% | -174.0% |
| 资本支出强度资本支出/营收 | 4.6% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $34.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PLBCRGNX
| Q4 25 | $21.6M | $-52.3M | ||
| Q3 25 | $5.6M | $-56.0M | ||
| Q2 25 | $2.1M | $-49.3M | ||
| Q1 25 | $7.5M | $33.6M | ||
| Q4 24 | $30.5M | $-31.6M | ||
| Q3 24 | $8.0M | $-40.5M | ||
| Q2 24 | $5.1M | $-45.5M | ||
| Q1 24 | $9.2M | $-55.5M |
自由现金流PLBCRGNX
| Q4 25 | $20.3M | $-52.8M | ||
| Q3 25 | $4.8M | $-56.5M | ||
| Q2 25 | $2.0M | $-49.7M | ||
| Q1 25 | $7.3M | $32.6M | ||
| Q4 24 | $29.8M | $-32.7M | ||
| Q3 24 | $7.8M | $-40.9M | ||
| Q2 24 | $4.8M | $-46.0M | ||
| Q1 24 | $9.0M | $-56.0M |
自由现金流率PLBCRGNX
| Q4 25 | 70.9% | -174.0% | ||
| Q3 25 | 17.5% | -189.9% | ||
| Q2 25 | 9.9% | -232.8% | ||
| Q1 25 | 33.7% | 36.6% | ||
| Q4 24 | 141.0% | -154.2% | ||
| Q3 24 | 37.1% | -168.9% | ||
| Q2 24 | 23.5% | -206.2% | ||
| Q1 24 | 45.8% | -358.5% |
资本支出强度PLBCRGNX
| Q4 25 | 4.6% | 1.7% | ||
| Q3 25 | 2.9% | 1.7% | ||
| Q2 25 | 0.2% | 1.8% | ||
| Q1 25 | 0.8% | 1.2% | ||
| Q4 24 | 3.2% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 1.1% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率PLBCRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.09× | — | ||
| Q2 25 | 0.33× | — | ||
| Q1 25 | 1.04× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.02× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.46× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLBC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
